title: Hepatocyte proliferation and hepatomegaly induced by phenobarbital and 1,4-bis [2-(3,5-dichloropyridyloxy)] benzene is suppressed in hepatocyte-targeted glypican 3 transgenic mice.
abstract: Glypican 3 (GPC3) is a family of glycosylphosphatidylinositol-anchored, cell-surface heparan sulfate proteoglycans. Loss-of-function mutations of GPC3 cause Simpson-Golabi-Behmel syndrome characterized by overgrowth of multiple organs, including liver. Our previous study showed that in GPC3 transgenic (TG) mice, hepatocyte-targeted overexpression of GPC3 suppresses hepatocyte proliferation and liver regeneration after partial hepatectomy and alters gene expression profiles and potential cell cycle-related proteins. This study investigates the role of GPC3 in hepatocyte proliferation and hepatomegaly induced by the xenobiotic mitogens phenobarbital (PB) and TCPOBOP (1, 4-bis [2-(3, 5-dichloropyridyloxy)] benzene). Wildtype (WT) and GPC3 TG mice were given 0.1% PB in drinking water for 10 days or a single dose of TCPOBOP (3 mg/kg) by oral gavage. At day 5 the WT mice showed a 2.2- and 3.0-fold increase in liver weight, whereas the GPC3 TG mice showed a 1.3- and 1.6-fold increase in liver weight after PB and TCPOBOP administration, respectively. There was a significant suppression of proliferative response in the GPC3 TG mice, as assessed by percent of Ki67-positive hepatocyte nuclei. Moreover, gene array analysis showed a panel of changes in the gene expression profile of TG mice, both before and after administration of the xenobiotic mitogens. Expression of cell cycle-related genes in the TG mice was also decreased compared to the WT mice.
  
  
  CONCLUSIONS
  Our results indicate that in GPC3 TG mice, hepatocyte-targeted overexpression of GPC3 plays an important role for regulation of liver size and termination of hepatocyte proliferation induced by the xenobiotic mitogens PB and TCPOBOP, comparable to the effects seen in the GPC3 TG mice during liver regeneration after partial hepatectomy.
authors.affiliation: Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
authors.forename: Chih-Wen
authors.initials: CW
authors.lastname: Lin
authors.forename: Wendy M
authors.initials: WM
authors.lastname: Mars
authors.forename: Shirish
authors.initials: S
authors.lastname: Paranjpe
authors.forename: Shashikiran
authors.initials: S
authors.lastname: Donthamsetty
authors.forename: Vishakha S
authors.initials: VS
authors.lastname: Bhave
authors.forename: Liang-I
authors.initials: LI
authors.lastname: Kang
authors.forename: Anne
authors.initials: A
authors.lastname: Orr
authors.forename: William C
authors.initials: WC
authors.lastname: Bowen
authors.forename: Aaron W
authors.initials: AW
authors.lastname: Bell
authors.forename: George K
authors.initials: GK
authors.lastname: Michalopoulos
mesh_terms: D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects*; D005786:Gene Expression Regulation; D018816:Genes, cdc; D053673:Glypicans / Q000235:genetics*; D022781:Hepatocytes / Q000187:drug effects* / Q000502:physiology*; D006529:Hepatomegaly / Q000139:chemically induced / Q000235:genetics*; D051379:Mice; D008822:Mice, Transgenic; D010634:Phenobarbital / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*
chemical_list: D053673:Glypicans; D011725:Pyridines; C028474:1,4-bis(2-(3,5-dichloropyridyloxy))benzene; D010634:Phenobarbital